RxDoctor Payments Data

Keri Wong, MD

Urogynecology and Reconstructive Pelvic Surgery · Litchfield Park, AZNPI 1639321284

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.5%), education and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Caldera Medical, Inc at 43.4% of the total. Reporting peaked in 2021 at $3,232 and has fallen 77.8% since, to $717 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in AZ, where the typical reported total is $8,817.

$8,817in general payments, 2019–2025

Across 156 payments — averaging $56.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$4K
  • Intuitive Surgical$3K
  • Medtronic$608
  • Astellas Pharma US Inc$238
  • Axonics, Inc.$184
  • Coopersurgical, Inc.$119
  • plus $814 from 18 others

What the payments were for

  • Consulting fees$1,60018%
  • Food & beverage$3,91944%
  • Education$3,06535%
  • Gifts$2333%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,817 in reported general payments places this provider in the 50th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.

See all urogynecology and reconstructive pelvic surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$146,505
Medicare patients
297
Services billed
1,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron121$86,194
GemtesaVibegron25$26,848
Estradiol238$17,639
Oxybutynin Chloride ErOxybutynin Chloride105$2,457
Methenamine Hippurate27$2,059
NitrofurantoinNitrofurantoin Macrocrystal65$1,494
Tolterodine Tartrate ErTolterodine Tartrate14$1,046
Solifenacin Succinate22$800
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$196
Cephalexin76$193
Ciprofloxacin Hcl49$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$238$86,194121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.

Other urogynecology and reconstructive pelvic surgery in Litchfield Park

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →